Islatravir and Methadone Pharmacokinetics (MK-8591-029)
Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
The present study is designed to determine the effect of islatravir (ISL) [MK-8591] on
methadone pharmacokinetics (PK). The primary objective is to assess whether ISL impacts the
area under the plasma concentration time curve from dosing to 24 hours postdose (AUC0-24) of
S-methadone and R-methadone in participants on oral methadone therapy. It is hypothesized
that the plasma AUC0-24hr for S- and R-methadone will be similar after single-dose
co-administration of methadone + ISL.